Deltex Medical Group PLC Results from head to head trial presented
July 11 2016 - 1:00AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
11 July 2016
11 July 2016
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Results from head to head trial presented
Significantly better outcomes from ODM
Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in
oesophageal Doppler monitoring ("ODM"), today announces initial
results from the first randomised controlled trial to compare
post-operative outcomes when using ODM to the most commonly used
alternative technology.
Doctors from St Thomas' Hospital, London, presented the findings
from their study of 127 patients at the annual meeting of The
Association of Coloproctology of Great Britain and Ireland. All
patients were undergoing bowel surgery, 40% of them using
laparoscopic ('keyhole') techniques, within a well established
enhanced recovery programme. Each was monitored with both
CardioQ-ODM and an uncalibrated Pulse Pressure Waveform Analysis
("PPWA") monitor which was originally developed at St Thomas'
Hospital for intensive care use about 25 years ago: in half the
patients care was guided using ODM and in the other half using
PPWA.
Statistically significant results included:
-- "Poor agreement": the PPWA device prompted a different
intervention to that indicated by ODM two times in every five,
resulting in either too much or too little fluid being given at
that time
-- 50% more PPWA patients required treatment with vaso-active drugs
-- ODM patients were able to get out of bed and move around on average one day sooner
-- ODM patients went home on average two days earlier (six days compared to eight days)
Prior to these results, there have been 13 studies using ODM
during surgery with positive outcomes (i.e. either a statistically
significant reduction in complications or length of stay or both)
and eight trials using this particular PPWA device during surgery
but no positive outcomes.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"These results confirm both the superiority of ODM over PPWA and
that intra-operative fluid management, done properly, has a crucial
role in determining optimal patient outcomes in modern enhanced
recovery programmes incuding laparoscopic surgical techniques.
"This is the second important new trial to be presented since we
launched our new, easier to use, TruFlow probes in May. The first
trial from Spain, the largest ever randomised controlled trial of
ODM, showed significant reductions in both post-operative
complications and length of hospital stay and this second study
shows why all the key evidence in this field comes from use of
ODM."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Barry Curtis, Company
Secretary
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and over 650,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFXEFAXKEAF
(END) Dow Jones Newswires
July 11, 2016 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024